2AB

VACCITECH (SP.ADR)/1

Healthcare · EUR · F

2AB

Price

€0.573

+1.24%

Cap

€27.37M

Earnings

30d Trend

+20.6%

2AB
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

69% annualised over 90 days

BRAIN47 SIGNAL

0
WEAK
Risk Level85
Quality37
Momentum20
Technical47
Fundamentals50

Raw weighted: 31×Macro 0.99 (1%)=31

RISK

85/100
90d Volatility
68.5%High
ATR %
8.6%High daily moves
Max Drawdown (1Y)
-72.6%Volatile

QUALITY

37/100
ROE (avg)
-89.5%*Negative
Piotroski F-Score
4/9Average
Accruals
-18.8%Cash earnings

MOMENTUM

20/100
12-1M Momentum
-33.3%Strong downtrend
6-1M Momentum
-26.1%Negative
1M Return
+14.7%Strong recent gains
Relative Strength
+0.3% vs sectorIn-line

TECHNICAL

47/100
RSI (14)
58.3Neutral
Price vs SMA200
-18.6%Bearish trend
MACD
0.00Bearish momentum
Bollinger Band
80%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.246Noisy/choppy

FUNDAMENTALS

50/100

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months54
3-12 months40
1-5+ years35

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate VACCITECH (SP.ADR)/1 at 31/100 — a WEAK reading on the Brain47 Signal. The strongest factor is fundamentals at 50/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

+14.7%

3 MONTHS

+19.8%

12 MONTHS

-18.5%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Fundamentals (50) and Technical (47) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 69%. I classify this as a speculative position — elevated volatility at 69% and smaller market cap define the opportunity.

speculativeScore: 31/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.